{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Belantamab+Mafodotin&page=2", "query": { "intervention": "Belantamab Mafodotin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 46, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Belantamab+Mafodotin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Belantamab+Mafodotin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T16:03:43.604Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07217184", "title": "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-07-29", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217184" }, { "nct_id": "NCT07217119", "title": "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Feladilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-11-26", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Madison, Wisconsin", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217119" }, { "nct_id": "NCT05117008", "title": "Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Relapse Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-07-19", "completion_date": "2024-01-15", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05117008" }, { "nct_id": "NCT04246047", "title": "Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 494, "start_date": "2020-05-07", "completion_date": "2028-06-30", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 5, "location_summary": "Yuma, Arizona • Denver, Colorado • Kansas City, Kansas + 2 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Fairfield", "state": "Ohio" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246047" }, { "nct_id": "NCT04892264", "title": "Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Plasma Cell Myeloma", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Belantamab Mafodotin", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Skeletal Survey X-Ray", "type": "PROCEDURE" }, { "name": "Low Dose Computed Tomography of the Whole Body", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2021-06-03", "completion_date": "2024-03-18", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04892264" }, { "nct_id": "NCT04676360", "title": "Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Plasmablastic Lymphoma", "Refractory Plasmablastic Lymphoma", "Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma" ], "interventions": [ { "name": "Belantamab Mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacob Soumerai, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-07-01", "completion_date": "2024-11-26", "has_results": true, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04676360" }, { "nct_id": "NCT04643002", "title": "Isatuximab in Combination With Novel Agents in RRMM - Master Protocol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plasma Cell Myeloma Refractory" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pegenzileukin", "type": "DRUG" }, { "name": "SAR439459", "type": "DRUG" }, { "name": "Belumosudil", "type": "DRUG" }, { "name": "Evorpacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2021-01-25", "completion_date": "2028-04-20", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04643002" }, { "nct_id": "NCT05091372", "title": "Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma Multiple" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2022-12-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091372" }, { "nct_id": "NCT05493618", "title": "Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma, Refractory" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-12", "completion_date": "2025-11", "has_results": false, "last_update_posted_date": "2023-01-27", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Neptune City", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05493618" }, { "nct_id": "NCT05986682", "title": "Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Blenrep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 30, "start_date": "2023-09-18", "completion_date": "2023-11-07", "has_results": true, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-02T16:03:43.604Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05986682" } ] }